PDF herunterladen
Aktuelle Kardiologie 2013; 2(3): 171-176
DOI: 10.1055/s-0032-1328484
Übersichtsarbeit
Georg Thieme Verlag KG Stuttgart · New York

Pharmakotherapie der arteriellen Hypertonie

Pharmacotherapy of Arterial Hypertension
W. Zidek
Med. Klinik IV, Charité Universitätsmedizin Berlin
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
11. Juni 2013 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Zusammenfassung

Die Indikation zur medikamentösen Behandlung richtet sich neben der Blutdruckhöhe nach dem kardiovaskulären Gesamtrisiko. Antihypertensiva der ersten Wahl sind Diuretika, Betablocker, RAS-Blocker (ACE-Hemmer und AT1-Blocker) und Kalziumantagonisten. In Abhängigkeit vom kardiovaskulären Risiko wird die Behandlung als Monotherapie oder sofort als Kombinationstherapie begonnen. Die Antihypertensiva der zweiten Wahl sind bei Versagen der Medikamente erster Wahl sowie in speziellen klinischen Situationen hilfreich. Bei Versagen der medikamentösen Therapie sind die neueren invasiven Therapieverfahren zu erwägen.

Abstract

The indication for antihypertensive treatment is not only determined by the height of blood pressure but also by the total cardiovascular risk. First-line antihypertensive agents are diuretics, beta blockers, RAS blockers (ACE inhibitors and AT1 blockers) as well as calcium antagonists. Depending on cardiovascular risk treatment is started as monotherapy or directly as combination therapy. Second line antihypertensive drugs may be helpful after first-line antihypertensive drugs failed and in special clinical situations. If drug treatment fails the novel invasive procedures have to be considered for treatment of hypertension.

Schlüsselwörter

Hypertonie - Pharmakotherapie - Antihypertensiva

Key words

hypertension - pharmacotherapy - antihypertensives
 

  • Literatur

  • 1 Hammarstrom S, Bechgaard P. Prognosis in arterial hypertension; comparison between 251 patients after sympathectomy and selected series of 435 non-operated patients. Am J Med 1950; 8: 53-56
    CrossrefPubMedGoogle Scholar
  • 2 Cushman WC, Evans GW, Byington RP et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010; 362: 1575-1585
    CrossrefPubMedGoogle Scholar
  • 3 Appel LJ, Wright jr. JT, Greene T et al. Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 2010; 363: 918-929
    CrossrefPubMedGoogle Scholar
  • 4 Klahr S, Levey A, Beck G et al. The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. N Engl J Med 1994; 330: 877-884
    CrossrefPubMedGoogle Scholar
  • 5 Aronow WS. Current role of beta-blockers in the treatment of hypertension. Expert Opin Pharmacother 2010; 11: 2599-2607
    CrossrefPubMedGoogle Scholar
  • 6 Elliott WJ, Childers WK. Should beta blockers no longer be considered first-line therapy for the treatment of essential hypertension without comorbidities?. Curr Cardiol Rep 2011; 13: 507-516
    CrossrefPubMedGoogle Scholar
  • 7 Ahimastos AA, Walker PJ, Askew C et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA 2013; 309: 453-460
    CrossrefPubMedGoogle Scholar
  • 8 Jafar TH, Schmid CH, Landa M et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001; 135: 73-87
    CrossrefPubMedGoogle Scholar
  • 9 Dahlöf B, Sever PS, Poulter NR et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366: 895-906
    CrossrefPubMedGoogle Scholar
  • 10 Jamerson K, Weber MA, Bakris GL et al. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med 2008; 359: 2417-2428
    CrossrefPubMedGoogle Scholar
  • 11 Bakris GL, Sarafidis PA, Weir MR et al. Renal outcomes with different fixed-dose combination therapies in patients with hypertension at high risk for cardiovascular events (ACCOMPLISH): a prespecified secondary analysis of a randomised controlled trial. Lancet 2010; 375: 1173-1181
    CrossrefPubMedGoogle Scholar
  • 12 Yusuf S, Teo KK, Pogue J et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008; 358: 1547-1559
    CrossrefPubMedGoogle Scholar
  • 13 Parving HH, Brenner BM, McMurray JJ et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012; 367: 2204-2213
    CrossrefPubMedGoogle Scholar
  • 14 Beckett NS, Peters R, Fletcher AE et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358: 1887-1898
    CrossrefPubMedGoogle Scholar